CHMP Adopted Positive Opinion for ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
– The CHMP recommended approval of ELZONRIS for the first line treatment of adult patients with BPDCN – If approved by the European Commission, ELZONRIS will be the first approved treatment for patients with BPDCN, and the first approved CD123-targeted therapy, in Europe The Menarini Group, a privately held Italian pharmaceutical and diagnostics company, announced […]
